HER-2 positive
|
Gastroesophageal Cancer
|
HER-2 positive
|
Gastroesophageal Cancer
|
trastuzumab Sensitive: A2 - Guideline
|
trastuzumab Sensitive: A2 - Guideline
|
PD-L1 overexpression
|
Gastroesophageal Cancer
|
PD-L1 overexpression
|
Gastroesophageal Cancer
|
PD1 inhibitor Sensitive: B - Late Trials
|
PD1 inhibitor Sensitive: B - Late Trials
|
PD-L1 overexpression
|
Gastroesophageal Cancer
|
PD-L1 overexpression
|
Gastroesophageal Cancer
|
PD-L1 inhibitor Sensitive: B - Late Trials
|
PD-L1 inhibitor Sensitive: B - Late Trials
|
HER-2 amplification
|
Gastroesophageal Cancer
|
HER-2 amplification
|
Gastroesophageal Cancer
|
trastuzumab Sensitive: B - Late Trials
|
trastuzumab Sensitive: B - Late Trials
|
PD-L1 expression
|
Gastroesophageal Cancer
|
PD-L1 expression
|
Gastroesophageal Cancer
|
pembrolizumab Sensitive: C1 - Off-label
|
pembrolizumab Sensitive: C1 - Off-label
|
HER-2 positive
|
Gastroesophageal Cancer
|
HER-2 positive
|
Gastroesophageal Cancer
|
pembrolizumab + trastuzumab Sensitive: C1 - Off-label
|
pembrolizumab + trastuzumab Sensitive: C1 - Off-label
|
HER-2 positive
|
Gastroesophageal Cancer
|
HER-2 positive
|
Gastroesophageal Cancer
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
TP53 mutation
|
Gastroesophageal Cancer
|
TP53 mutation
|
Gastroesophageal Cancer
|
Immunotherapy Resistant: C3 – Early Trials
|
Immunotherapy Resistant: C3 – Early Trials
|
TET1 mutation
|
Gastroesophageal Cancer
|
TET1 mutation
|
Gastroesophageal Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
HER-2 expression
|
Gastroesophageal Cancer
|
HER-2 expression
|
Gastroesophageal Cancer
|
ZW25 Sensitive: C3 – Early Trials
|
ZW25 Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Gastroesophageal Cancer
|
PD-L1 expression
|
Gastroesophageal Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Gastroesophageal Cancer
|
HER-2 overexpression
|
Gastroesophageal Cancer
|
disitamab vedotin Sensitive: C3 – Early Trials
|
disitamab vedotin Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Gastroesophageal Cancer
|
PD-L1 expression
|
Gastroesophageal Cancer
|
tislelizumab Sensitive: C3 – Early Trials
|
tislelizumab Sensitive: C3 – Early Trials
|
FGFR2 amplification
|
Gastroesophageal Cancer
|
FGFR2 amplification
|
Gastroesophageal Cancer
|
ABSK091 Sensitive: C3 – Early Trials
|
ABSK091 Sensitive: C3 – Early Trials
|
MET amplification
|
Gastroesophageal Cancer
|
MET amplification
|
Gastroesophageal Cancer
|
crizotinib Sensitive: C3 – Early Trials
|
crizotinib Sensitive: C3 – Early Trials
|
TGFB1 elevation
|
Gastroesophageal Cancer
|
TGFB1 elevation
|
Gastroesophageal Cancer
|
M7824 Sensitive: C3 – Early Trials
|
M7824 Sensitive: C3 – Early Trials
|
HER-2 overexpression
|
Gastroesophageal Cancer
|
HER-2 overexpression
|
Gastroesophageal Cancer
|
ZW25 Sensitive: C3 – Early Trials
|
ZW25 Sensitive: C3 – Early Trials
|
MET amplification
|
Gastroesophageal Cancer
|
MET amplification
|
Gastroesophageal Cancer
|
afatinib Resistant: C3 – Early Trials
|
afatinib Resistant: C3 – Early Trials
|
EGFR amplification + ERBB2 amplification
|
Gastroesophageal Cancer
|
EGFR amplification + ERBB2 amplification
|
Gastroesophageal Cancer
|
afatinib Sensitive: C3 – Early Trials
|
afatinib Sensitive: C3 – Early Trials
|
CFB overexpression
|
Gastroesophageal Cancer
|
CFB overexpression
|
Gastroesophageal Cancer
|
sunitinib Sensitive: C3 – Early Trials
|
sunitinib Sensitive: C3 – Early Trials
|
VEGFC-H
|
Gastroesophageal Cancer
|
VEGFC-H
|
Gastroesophageal Cancer
|
sunitinib Sensitive: C3 – Early Trials
|
sunitinib Sensitive: C3 – Early Trials
|
HER-2 positive
|
Gastroesophageal Cancer
|
HER-2 positive
|
Gastroesophageal Cancer
|
pembrolizumab + margetuximab Sensitive: C3 – Early Trials
|
pembrolizumab + margetuximab Sensitive: C3 – Early Trials
|
POLE mutation
|
Gastroesophageal Cancer
|
POLE mutation
|
Gastroesophageal Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
POLD1 mutation
|
Gastroesophageal Cancer
|
POLD1 mutation
|
Gastroesophageal Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Gastroesophageal Cancer
|
PD-L1 expression
|
Gastroesophageal Cancer
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 inhibitor Sensitive: C3 – Early Trials
|
PD-L1 expression
|
Gastroesophageal Cancer
|
PD-L1 expression
|
Gastroesophageal Cancer
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
HER-2 positive + HER-2 amplification
|
Gastroesophageal Cancer
|
HER-2 positive + HER-2 amplification
|
Gastroesophageal Cancer
|
trastuzumab Sensitive: C3 – Early Trials
|
trastuzumab Sensitive: C3 – Early Trials
|
CTAG1A expression
|
Gastroesophageal Cancer
|
CTAG1A expression
|
Gastroesophageal Cancer
|
Immunotherapy Sensitive: C3 – Early Trials
|
Immunotherapy Sensitive: C3 – Early Trials
|
HER-2 positive + PD-L1 expression
|
Gastroesophageal Cancer
|
HER-2 positive + PD-L1 expression
|
Gastroesophageal Cancer
|
margetuximab + retifanlimab Sensitive: C3 – Early Trials
|
margetuximab + retifanlimab Sensitive: C3 – Early Trials
|
HER-2 mutation
|
Gastroesophageal Cancer
|
HER-2 mutation
|
Gastroesophageal Cancer
|
dasatinib Sensitive: D – Preclinical
|
dasatinib Sensitive: D – Preclinical
|
HER-2 mutation
|
Gastroesophageal Cancer
|
HER-2 mutation
|
Gastroesophageal Cancer
|
neratinib Sensitive: D – Preclinical
|
neratinib Sensitive: D – Preclinical
|
HER-2 mutation
|
Gastroesophageal Cancer
|
HER-2 mutation
|
Gastroesophageal Cancer
|
dasatinib + neratinib Sensitive: D – Preclinical
|
dasatinib + neratinib Sensitive: D – Preclinical
|
BCL2 overexpression + MCL1 overexpression
|
Gastroesophageal Cancer
|
BCL2 overexpression + MCL1 overexpression
|
Gastroesophageal Cancer
|
AT 101 Sensitive: D – Preclinical
|
AT 101 Sensitive: D – Preclinical
|
ERBB2 G778A + CCNE1 amplification
|
Gastroesophageal Cancer
|
ERBB2 G778A + CCNE1 amplification
|
Gastroesophageal Cancer
|
AZD1775 + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
AZD1775 + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
HER2 underexpression + CCNE1 amplification
|
Gastroesophageal Cancer
|
HER2 underexpression + CCNE1 amplification
|
Gastroesophageal Cancer
|
AZD1775 + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
AZD1775 + fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
HER2 amplification + CCNE1 expression
|
Gastroesophageal Cancer
|
HER2 amplification + CCNE1 expression
|
Gastroesophageal Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
HER2 overexpression + CCNE1 amplification
|
Gastroesophageal Cancer
|
HER2 overexpression + CCNE1 amplification
|
Gastroesophageal Cancer
|
fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
fam-trastuzumab deruxtecan-nxki Sensitive: D – Preclinical
|
MET amplification
|
Gastroesophageal Cancer
|
MET amplification
|
Gastroesophageal Cancer
|
savolitinib + capmatinib Sensitive: D – Preclinical
|
savolitinib + capmatinib Sensitive: D – Preclinical
|